Contrast agents in patients on dialysis

Area of Science:

• Radiology and Nephrology
• Pharmacology and Toxicology

Background:

• Contrast media are essential for enhancing diagnostic information in various imaging modalities like X-ray, MRI, and ultrasound.
• Water-soluble, iodinated intravascular agents are frequently used in high doses and are primarily excreted by the kidneys.
• Potential nephrotoxic effects of these contrast agents pose challenges in patients with pre-existing renal impairment.

Purpose of the Study:

• To review the chemical composition and pharmacokinetics of iodinated contrast agents.
• To evaluate the potential toxic effects of contrast media on cardiac, neural, renal, and endothelial tissues.
• To discuss the safety of contrast agents in patients with end-stage renal disease (ESRD) and those undergoing dialysis, including MRI and US contrast agents.

Main Methods:

• Literature review of chemical properties and pharmacokinetic profiles of contrast agents.
• Analysis of studies detailing the toxicological effects on various organ systems.
• Discussion of clinical safety data for contrast media use in renally compromised patients.

Main Results:

• Iodinated contrast media, while vital for imaging, carry risks of nephrotoxicity.
• Adverse effects can impact the heart, neural tissues, kidneys, and endothelium.
• Safety profiles for contrast agents in ESRD patients and those on dialysis require careful assessment.

Conclusions:

• The use of iodinated contrast media in patients with renal impairment, including those with ESRD and on dialysis, necessitates a thorough risk-benefit evaluation.
• Understanding the pharmacokinetics and potential toxicities is key to safe administration.
• Further research and cautious application are advised for contrast-enhanced imaging in vulnerable patient groups.